| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2734 |
| Trial ID | NCT04969601 |
| Disease | Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia |
| Phase | Phase1|Phase2 |
| Recruitment status | Unknown |
| Title | Anti-Covid-19 Vaccine Protection in Immunocompromised Children (1 to 15 Years Old) With Acute Leukemia and Their Siblings (≥12 Years Old). Phase I-II Trial Evaluating Post-vaccine Safety and Humoral and Cellular Immunogenicity |
| Year | 2021 |
| Country | France |
| Company sponsor | Assistance Publique - Hôpitaux de Paris |
| Other ID(s) | APHP210639 |
| Vector information | |||
|
|||
| Cohort1: COMIRNATY__dose level 1 | |||||||
|
|||||||
| Cohort2: COMIRNATY__dose level 2 | |||||||
|
|||||||
| Cohort3: COMIRNATY__dose level 3 | |||||||
|
|||||||